Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

January 22, 2024

Study Completion Date

March 30, 2024

Conditions
Hypertension
Interventions
OTHER

Standard Care

Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.

OTHER

Intensive Treatment

Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Texas Health Resources

OTHER

collaborator

Michigan State University

OTHER

collaborator

National Institute on Aging (NIA)

NIH

lead

University of Texas Southwestern Medical Center

OTHER

NCT03354143 - Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) | Biotech Hunter | Biotech Hunter